Catalent

Company Description

Catalent, Inc. (NYSE: CTLT), an S&P 500® company, is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs, including Moderna's COVID-19 mRNA vaccine (https://www.catalent.com/covid-19/), Sarepta’s most advanced gene therapy candidate for the treatment of Duchenne muscular dystrophy (https://investorrelations.sarepta.com/node/22371/pdf), and GLP-1 agonists for diabetes and weight loss, like Ozempic and Trulicity (https://www.catalent.com/catalent-news/novo-holdings-to-acquire-catalent/). Catalent helps accelerate over 1,500 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply approximately 70 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of nearly 18,000 includes more than 3,000 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated nearly $4.3 billion in revenue in its 2023 fiscal year.